Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod® product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod® technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 100,000 users across the globe rely on Insulet’s Omnipod® Insulin Management System to bring simplicity and freedom to their lives.
Starting July 1, 2018, Insulet will assume direct distribution of its Omnipod® Insulin Management System in Europe, including sales, marketing, training and customer support activities. This will allow Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as it already does in the United States and Canada. European customers can find additional information about our transition at www.omnipodeurope.com and can also register for email updates. For information about the current distribution of the Omnipod® Insulin Management System in Europe and support before July 1, 2018, please visit mylife_OmniPod.
Learn more about Insulet, an innovative medical device company based in Billerica, MA.
Interested in a career at Insulet, and care about improving the lives of people with diabetes?
Partner with Insulet Delivery Systems Group to deliver the full potential of your drug via the Omnipod® System.
600 Technology Park Drive, Ste 200 Billerica, MA 01821
From outside the US:
Confidential customer fax: